​

Regeneron Pharmaceuticals (REGN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

REGN Stock Forecast

Regeneron Pharmaceuticals (REGN) stock forecast, based on 48 Wall Street analysts, predicts a 12-month average price target of $807.71, with a high of $1,057.00 and a low of $637.00. This represents a 7.19% increase from the last price of $753.55.

$600 $720 $840 $960 $1 $1 High: $1057 Avg: $807.71 Low: $637 Last Closed Price: $753.55

REGN Stock Rating

Regeneron Pharmaceuticals stock's rating consensus is Buy, based on 48 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 34 Buy (70.83%), 14 Hold (29.17%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 48 14 34 0 Strong Sell Sell Hold Buy Strong Buy

REGN Price Target Upside V Benchmarks

TypeNameUpside
StockRegeneron Pharmaceuticals7.19%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts22132
Avg Price Target$894.50$795.62$767.13
Last Closing Price$753.55$753.55$753.55
Upside/Downside18.70%5.58%1.80%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 262148-125
Dec, 253167-127
Nov, 254155-125
Oct, 254156-126
Sep, 253147-125
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 22, 2026Evercore ISI$875.00$761.5614.90%16.12%
Jan 08, 2026Goldman Sachs$914.00$812.2712.52%21.29%
Dec 17, 2025Andrew BerensLeerink Partners$873.00$746.3616.97%15.85%
Dec 12, 2025Terence FlynnMorgan Stanley$768.00$741.523.57%1.92%
Dec 10, 2025HSBC$985.00$692.5842.22%30.71%
Dec 04, 2025Evan SeigermanBMO Capital$850.00$723.6717.46%12.80%
Dec 04, 2025Canaccord Genuity$1.06K$723.6746.06%40.27%
Nov 24, 2025Truist Financial$798.00$766.504.11%5.90%
Nov 24, 2025Scotiabank$770.00$769.230.10%2.18%
Nov 24, 2025HSBC$890.00$755.9017.74%18.11%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 22, 2026Evercore ISIOutperformOutperformhold
Jan 08, 2026Goldman SachsBuyBuyhold
Jan 07, 2026CitigroupBuyBuyhold
Dec 17, 2025JefferiesBuyBuyhold
Dec 10, 2025HSBCBuyBuyhold
Dec 04, 2025BMO CapitalOutperformOutperformhold
Dec 02, 2025BernsteinOutperformOutperformhold
Nov 24, 2025ScotiabankSector PerformSector Performhold
Nov 24, 2025HSBCBuyinitialise
Nov 20, 2025Wells FargoPositivePositivehold

Financial Forecast

EPS Forecast

$30 $40 $50 $60 $70 $80 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$76.40$40.51$37.05$40.90----
Avg Forecast$71.52$42.60$42.62$45.02$44.51$48.41$56.23$61.14
High Forecast$74.49$45.65$43.60$47.01$52.39$60.93$71.36$66.97
Low Forecast$67.49$40.10$39.84$43.54$34.72$38.38$43.10$56.27
Surprise %6.82%-4.91%-13.07%-9.15%----

Revenue Forecast

$11B $13B $15B $16B $18B $20B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$16.07B$12.17B$13.12B$14.20B----
Avg Forecast$15.70B$11.86B$12.94B$14.18B$14.63B$15.52B$17.22B$18.20B
High Forecast$16.20B$12.52B$13.07B$14.49B$15.28B$15.58B$17.22B$19.53B
Low Forecast$15.02B$11.33B$12.65B$14.04B$13.90B$15.46B$17.21B$17.08B
Surprise %2.39%2.62%1.37%0.15%----

Net Income Forecast

$3B $4B $5B $7B $8B $9B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$8.08B$4.34B$3.95B$4.41B----
Avg Forecast$7.29B$4.49B$3.95B$5.15B$4.36B$4.65B$5.30B$6.95B
High Forecast$8.75B$5.39B$4.74B$5.34B$5.96B$6.93B$8.11B$7.61B
Low Forecast$5.83B$3.59B$3.16B$4.95B$3.95B$4.36B$4.90B$6.40B
Surprise %10.75%-3.36%--14.28%----

REGN Forecast FAQ

Is Regeneron Pharmaceuticals stock a buy?

Regeneron Pharmaceuticals stock has a consensus rating of Buy, based on 48 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 34 Buy, 14 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Regeneron Pharmaceuticals is a favorable investment for most analysts.

What is Regeneron Pharmaceuticals's price target?

Regeneron Pharmaceuticals's price target, set by 48 Wall Street analysts, averages $807.71 over the next 12 months. The price target range spans from $637 at the low end to $1.06K at the high end, suggesting a potential 7.19% change from the previous closing price of $753.55.

How does Regeneron Pharmaceuticals stock forecast compare to its benchmarks?

Regeneron Pharmaceuticals's stock forecast shows a 7.19% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Regeneron Pharmaceuticals over the past three months?

  • January 2026: 8.00% Strong Buy, 56.00% Buy, 32.00% Hold, 0% Sell, 4.00% Strong Sell.
  • December 2025: 11.11% Strong Buy, 59.26% Buy, 25.93% Hold, 0% Sell, 3.70% Strong Sell.
  • November 2025: 16.00% Strong Buy, 60.00% Buy, 20.00% Hold, 0% Sell, 4.00% Strong Sell.

What is Regeneron Pharmaceuticals’s EPS forecast?

Regeneron Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $44.51, marking a 8.83% increase from the reported $40.9 in 2024. Estimates for the following years are $48.41 in 2026, $56.23 in 2027, and $61.14 in 2028.

What is Regeneron Pharmaceuticals’s revenue forecast?

Regeneron Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $14.63B, reflecting a 3.00% increase from the reported $14.2B in 2024. The forecast for 2026 is $15.52B, followed by $17.22B for 2027, and $18.2B for 2028.

What is Regeneron Pharmaceuticals’s net income forecast?

Regeneron Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $4.36B, representing a -1.23% decrease from the reported $4.41B in 2024. Projections indicate $4.65B in 2026, $5.3B in 2027, and $6.95B in 2028.